Bristol Myers Squibb (BMY)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
$57.98+2.25%
Close 2026-07-07 · 1-day change
Reading BMY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BMY free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
Reading BMY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BMY free→QuarterlyIQ Insights · BMY
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On April 30, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the first quarter of 2026. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On February 5, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the fourth quarter of 2025 and full year of 2025. A copy of the Earnings Press Release is furnished pursuant to this
Other Events. Indenture On November 10, 2025, BMS Ireland Capital Funding Designated Activity Company (the “Issuer”), a designated activity company incorporated under the laws of Ireland and a wholly-owned subsidiary of Bristol-Myers Squibb Company (the “Company”), completed the public offering (the “Offering”) of (i) €750,000,000 aggregate principal amount of 2.973% Notes due 2030 (the “2030 Notes”), (ii) €1,150,000,000 aggregate principal amount of 3.363% Notes due 2033 (the “2033 Notes”),…
Results of Operations and Financial Condition. On October 30, 2025, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the third quarter of 2025. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On July 31, 2025, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the second quarter of 2025. A copy of the Earnings Press Release is furnished pursuant to this
Chief Medical Officer and Head of Development, Executive Vice President — Dr. Samit Hirawat: Dr. Hirawat is leaving the company and transitioning to an advisory role.
Results of Operations and Financial Condition. On April 24, 2025, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the first quarter of 2025. A copy of the Earnings Press Release is furnished pursuant to this
Executive Vice President, General Counsel — Sandra Leung: Sandra Leung intends to retire from her position with a planned transition period.
Results of Operations and Financial Condition. On February 6, 2025, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the fourth quarter of 2024 and full year of 2024. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On October 31, 2024, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the third quarter of 2024. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On July 26, 2024, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the second quarter of 2024. A copy of the Earnings Press Release is furnished pursuant to this
Director — Michael R. McMullen: Mr. Michael R. McMullen was elected to the Board of Directors, effective July 1, 2024.
Results of Operations and Financial Condition. On April 25, 2024, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the first quarter of 2024. A copy of the Earnings Press Release is furnished pursuant to this
Director — Mr. Gerald Storch: Mr. Gerald Storch will not stand for re-election to the Board of Directors at the 2024 Annual Meeting.
Other Events. On March 18, 2024, Bristol-Myers Squibb Company (“BMS”) issued a press release announcing the completion of its previously announced acquisition (the “Acquisition”) of Karuna Therapeutics, Inc. (“Karuna”). In the Acquisition, each share of Karuna common stock issued and outstanding immediately prior to the effective time of the Acquisition (other than certain excluded shares as described in the agreement and plan of merger entered into among BMS, Karuna and Miramar Merger Sub In…
does not purport to be complete and is qualified in its entirety by reference to the full text of the Base Indenture, the Fifteenth Supplemental Indenture and the Notes. The Base Indenture was filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K dated May 27, 1993 and filed on June 3, 1993 and the terms of which are incorporated herein by reference. The Fifteenth Supplemental Indenture is filed as Exhibit 4.1 to this Current Report on Form 8-K and its terms are incorporated herein…
Other Events. Indenture On February 22, 2024, Bristol-Myers Squibb Company (the “Company”) completed the public offering (the “Offering”) of (i) $500,000,000 aggregate principal amount of Floating Rate Notes due 2026 (the “Floating Rate Notes”), (ii) $1,000,000,000 aggregate principal amount of 4.950% Notes due 2026 (the “2026 Notes”) (iii) $1,000,000,000 aggregate principal amount of 4.900% Notes due 2027 (the “2027 Notes”), (iv) $1,750,000,000 aggregate principal amount of 4.900% Notes due…
Senior Vice President and Controller — Phil Holzer: Mr. Phil Holzer was promoted to Senior Vice President and Controller, while Ms. Sharon Greenlees will assume another role at the company.
Results of Operations and Financial Condition. On February 2, 2024, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the fourth quarter of 2023 and full year of 2023. A copy of the Earnings Press Release is furnished pursuant to this
Other Events. On December 22, 2023, Bristol-Myers Squibb Company (“BMS”), and Karuna Therapeutics, Inc. (“Karuna”), issued a joint press release announcing that BMS, Karuna and Miramar Merger Sub Inc., a wholly owned subsidiary of BMS (“Merger Sub”), have signed an agreement and plan of merger (the “Merger Agreement”) providing that, on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into Karuna, with Karuna surviving as a wholly owned subsidiary of B…
Other Events. Indenture On November 13, 2023, Bristol-Myers Squibb Company (the “Company”) completed the public offering (the “Offering”) of (i) $1,000,000,000 aggregate principal amount of 5.750% Notes due 2031, (ii) $1,000,000,000 aggregate principal amount of 5.900% Notes due 2033, (iii) $1,250,000,000 aggregate principal amount of 6.250% Notes due 2053, and (iv) $1,250,000,000 aggregate principal amount of 6.400% Notes due 2063 (collectively, the “Notes”). The Company intends to use the n…
CEO — Giovanni Caforio, M.D.: Dr. Giovanni Caforio is retiring as CEO and becoming Executive Chairman with Dr. Christopher Boerner appointed as the new CEO.
Results of Operations and Financial Condition. On October 26, 2023, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the third quarter of 2023. A copy of the Earnings Press Release is furnished pursuant to this
Other Events. On August 9, 2023, Bristol-Myers Squibb Company (“BMS”) entered into accelerated share repurchase (“ASR”) transactions under agreements with each of Bank of America, N.A., Citibank, N.A., JPMorgan Chase Bank, National Association and Morgan Stanley & Co. LLC (each, an “ASR Agreement” and collectively, the “ASR Agreements”), to repurchase an aggregate of $4.0 billion (the “Repurchase Price”) of BMS common stock, par value $0.10 per share (the “Common Stock”). The ASR transactions…
Results of Operations and Financial Condition. On July 27, 2023, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the second quarter of 2023. A copy of the Earnings Press Release is furnished pursuant to this
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.